TABLE 2.
Competing risk regression models for the association between a history of malignancies and the development of second primary malignancies after follicular lymphoma diagnosis in the Netherlands
| Univariable | Multivariable model 1 | Multivariable model 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SHR | 95% CI | P‐value* | SHR | 95% CI | P‐value* | SHR | 95% CI | P‐value* | |
| Prior malignancy diagnosis | |||||||||
| No | 1 | Reference | 1 | Reference | – | – | – | ||
| Yes | 1.44 | 1.15‐1.80 | .001 | 1.30 | 1.03‐1.64 | .027 | – | – | – |
| Prior malignancy diagnosis | |||||||||
| No | 1 | Reference | – | – | – | 1 | Reference | ||
| Yes with ST and/or RT | 1.49 | 1.09‐2.04 | .013 | – | – | – | 1.40 | 1.02‐1.93 | .039 |
| Yes without ST and/or RT | 1.40 | 1.02‐1.90 | .035 | – | – | – | 1.21 | 0.88‐1.67 | .233 |
| Sex | |||||||||
| Female | 1 | Reference | 1 | Reference | 1 | Reference | |||
| Male | 1.24 | 1.11‐1.40 | <.001 | 1.32 | 1.17‐1.49 | <.001 | 1.32 | 1.17‐1.48 | <.001 |
| Age at FL diagnosis, 10 years | 1.16 | 1.12‐1.20 | <.001 | 1.17 | 1.12‐1.22 | <.001 | 1.17 | 1.12‐1.22 | <.001 |
| Year of FL diagnosis | 1.00 | 0.99‐1.01 | .558 | 1.00 | 0.99‐1.01 | .529 | 1.00 | 0.98‐1.01 | .524 |
| Stage of FL at diagnosis | |||||||||
| I | 1 | Reference | 1 | Reference | 1 | Reference | |||
| II | 1.08 | 0.89‐1.30 | .452 | 1.07 | 0.88‐1.29 | .513 | 1.07 | 0.88‐1.29 | .519 |
| III | 0.88 | 0.73‐1.04 | .136 | 0.90 | 0.75‐1.07 | .243 | 0.90 | 0.75‐1.07 | .240 |
| IV | 0.96 | 0.82‐1.12 | .610 | 1.00 | 0.85‐1.16 | .957 | 1.00 | 0.85‐1.16 | .961 |
| Unknown | 0.75 | 0.47‐1.19 | .219 | 0.69 | 0.43‐1.11 | .128 | 0.69 | 0.43‐1.11 | .127 |
*
P‐values are compared with the reference category. Statistically significant P‐values (P < .05) are presented in bold.
Abbreviations: CI, confidence interval; FL, follicular lymphoma; RT, radiotherapy.; SHR, subdistribution hazard ratio; ST, systemic therapy.